Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xiehe Group To Set Up Base In Shenzhen

This article was originally published in PharmAsia News

Executive Summary

China's leading biopharmaceutical company, Shenyang Xiehe Group, has announced it will set up a wholly-owned subsidiary in Shenzhen High-Tech Industrial Park; it will also site its future R&D and international base in the city. Xiehe Group, a multinational conglomerate with 33 subsidiaries worldwide, integrates R&D, production and trading for health care items, biopharmaceuticals and other high-tech products. Its product value is expected to reach RMB 4 billion by 2010. The latest move is an important step in Xiehe Group's rapid growth as it will tap on Shenzhen's advantages in location and manufacturing to reap its R&D translational output as well as expand sales. The company has already established R&D centers in the U.S., Hong Kong and Shenyang. (Click here for more - Chinese Language)

You may also be interested in...



Gilead’s Comparative Analysis To Bolster Remdesivir Draws Criticism

Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.

US FDA Announces Plans To Resume Domestic Inspections

Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.

Finance Watch: Poseida, Nkarta And Inventiva Are July’s First Biopharma IPOs

Poseida, Nkarta and Inventiva raised $224m, $252m and $107.7m, respectively. Also, Forbion raised €185m ($208m) of a new €250m fund and Blackstone closed the last $1.2bn of its $4.6bn fund for public and private company deals, and Ascendis led recent follow-ons with a $569.2m offering.

UsernamePublicRestriction

Register

ID043835

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel